U.S. FDA approves Ziihera for first-line treatment of advanced gastric cancer

The agency granted approval for zanidatamab-hrii combined with or without tislelizumab and chemotherapy for HER2-positive gastroesophageal adenocarcinoma.

25 Aug, 14:23 — 25 Aug, 14:23

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual6d ago

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma - Taiwan News

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma Taiwan News

Read full article →

U.S. FDA approves Ziihera for first-line treatment of advanced gastric cancer

Sources

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma - Taiwan News

Related Stories

Spain Records Over 5,000 Heat-Related Deaths During Unprecedented Summer

Singer Lionel Richie Hospitalized in ICU Following Concert Medical Episode

Croatia Launches Mosquito Control Campaign Amid West Nile Virus Outbreak

Lionel Richie Hospitalized in ICU Following St. Louis Concert